These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20320214)

  • 1. The Administration of Iron.
    Lucas GH; Henderson VE
    Can Med Assoc J; 1936 Mar; 34(3):343-4. PubMed ID: 20320214
    [No Abstract]   [Full Text] [Related]  

  • 2. Intranasal administration of deferoxamine to iron overloaded patients.
    Gordon GS; Ambruso DR; Robinson WA; Githens JH
    Am J Med Sci; 1989 May; 297(5):280-4. PubMed ID: 2640419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients.
    Hoen B; Paul-Dauphin A; Kessler M
    Clin Nephrol; 2002 Jun; 57(6):457-61. PubMed ID: 12078950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration.
    Fredriksson A; Archer T
    Behav Brain Res; 2003 Feb; 139(1-2):31-46. PubMed ID: 12642174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Administration of iron-containing drugs in non-dialyzed patients with chronic kidney disease].
    Grzegorzewska AE
    Pol Arch Med Wewn; 2007 Apr; 117(4):52-7. PubMed ID: 17722476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceleration of iron utilization after intravenous iron administration during activated erythropoiesis in hemodialysis patients: a randomized study.
    Kuji T; Toya Y; Fujikawa T; Kakimoto-Shino M; Nishihara M; Shibata K; Tamura K; Hirawa N; Satta H; Kawata S; Kouguchi N; Umemura S
    Ther Apher Dial; 2015 Apr; 19(2):131-7. PubMed ID: 25257861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two different modalities of iron gluconate i.v. administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients.
    de Vecchi AF; Novembrino C; Lonati S; Ippolito S; Bamonti F
    Nephrol Dial Transplant; 2007 Jun; 22(6):1709-13. PubMed ID: 17298995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subchronic administration of haloperidol influences the functional deficits of postnatal iron administration in mice.
    Fredriksson A; Archer T
    Neurotox Res; 2006 Oct; 10(2):123-9. PubMed ID: 17062374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
    Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients.
    Gelone DK; Park JM; Lake KD
    Pharmacotherapy; 2007 Sep; 27(9):1272-8. PubMed ID: 17723081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous iron administration strategies and anemia management in hemodialysis patients.
    Michels WM; Jaar BG; Ephraim PL; Liu Y; Miskulin DC; Tangri N; Crews DC; Scialla JJ; Shafi T; Sozio SM; Bandeen-Roche K; Cook CJ; Meyer KB; Boulware LE;
    Nephrol Dial Transplant; 2017 Jan; 32(1):173-181. PubMed ID: 27604984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure.
    Lim CS; Vaziri ND
    Kidney Int; 2004 May; 65(5):1802-9. PubMed ID: 15086920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subchronic administration of haloperidol influences the functional deficits of postnatal iron administration in mice.
    Fredriksson A; Archer T
    Neurotox Res; 2006 Jun; 9(4):305-12. PubMed ID: 16782590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combating iron deficiency: daily administration of iron is far superior to weekly administration.
    Hallberg L
    Am J Clin Nutr; 1998 Aug; 68(2):213-7. PubMed ID: 9701172
    [No Abstract]   [Full Text] [Related]  

  • 18. [Oral iron administration through drinking water as compared with parenteral administration of iron dextran preparations in piglets].
    Meyer P; Matzke P; Peschke W; Kaufmann G
    Berl Munch Tierarztl Wochenschr; 1975 Nov; 88(21):409-12. PubMed ID: 1200962
    [No Abstract]   [Full Text] [Related]  

  • 19. Postnatal iron-induced motor behaviour alterations following chronic neuroleptic administration in mice.
    Fredriksson A; Eriksson P; Archer T
    J Neural Transm (Vienna); 2006 Feb; 113(2):137-50. PubMed ID: 16082515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum iron concentrations following administration of two different iron preparations.
    Danisi M; Guerresi E; Landucci G; Gori G; Ceccarelli G
    J Int Med Res; 1987; 15(6):374-8. PubMed ID: 3436485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.